Structure via PubChem · Public domain (PubChem)
پالبوسیکلیب
Sign in to saveAlso known as PD-0332991, PD0332991, PD 332991, PD 0332991, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.
Key facts
- Drug.image
- Palbociclib skeletal formula.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Palbociclib ball-and-stick model from xtal 2023.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Ibrance, others
- Drug.MedlinePlus
- a615013
- Drug.DailyMedID
- Palbociclib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EF01
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- 46%
- Drug.protein_bound
- 85%
via Wikipedia infobox
Chemical data
- Formula
- C24H29N7O2
- Molecular weight
- 447.5 g/mol
- IUPAC name
- 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-yl-2-pyridinyl)amino]pyrido[2,3-d]pyrimidin-7-one
- SMILES
- CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
- InChIKey
- AHJRHEGDXFFMBM-UHFFFAOYSA-N
- XLogP
- 1.8
- Polar surface area
- 103 Ų
- H-bond donors
- 2
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2015
- Admin. routes
- oral
- Indications
- breast carcinoma, Mantle cell lymphoma, breast neoplasm, neoplasm
via ChEMBL · EBI
Research
2,869 papers- Palbociclib and Letrozole in Advanced Breast Cancer.The New England journal of medicine · 2016
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.The Lancet. Oncology · 2016
- Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.Breast cancer research and treatment · 2019
- Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.Journal of global oncology · 2019
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 447.238
- Has use
- medication
Show 5 more facts
- chemical formula
- C₂₄H₂₉N₇O₂
- canonical SMILES
- CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
- World Health Organisation international non-proprietary name
- palbociclib
- subject has role
- protein kinase inhibitors
- Commons category
- Palbociclib
Sources (6)
via Wikidata · CC0